NextCure (NASDAQ:NXTC) Posts Quarterly Earnings Results, Misses Expectations By $0.85 EPS

NextCure (NASDAQ:NXTC) announced its quarterly earnings results on Thursday. The company reported ($2.80) EPS for the quarter, missing the consensus estimate of ($1.95) by ($0.85), FiscalAI reports.

NextCure Stock Up 4.5%

Shares of NXTC stock traded up $0.25 during trading on Friday, reaching $5.84. The company had a trading volume of 290,316 shares, compared to its average volume of 6,419,686. The firm’s 50 day simple moving average is $3.35 and its two-hundred day simple moving average is $8.41. NextCure has a one year low of $1.55 and a one year high of $15.74.

Insider Transactions at NextCure

In related news, major shareholder Adar1 Capital Management, Llc bought 36,303 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was purchased at an average price of $4.94 per share, with a total value of $179,336.82. Following the completion of the transaction, the insider directly owned 722,419 shares of the company’s stock, valued at $3,568,749.86. This trade represents a 5.29% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders purchased a total of 346,761 shares of company stock worth $1,710,807 over the last three months. 11.90% of the stock is owned by corporate insiders.

Institutional Trading of NextCure

Institutional investors and hedge funds have recently modified their holdings of the company. Ikarian Capital LLC bought a new stake in shares of NextCure during the 4th quarter worth $3,382,000. Squadron Capital Management LLC bought a new position in NextCure in the 4th quarter worth $3,363,000. Millennium Management LLC bought a new position in NextCure in the 4th quarter worth $185,000. Boothbay Fund Management LLC acquired a new position in NextCure during the 4th quarter worth $988,000. Finally, Marshall Wace LLP acquired a new position in NextCure during the 4th quarter worth $160,000. 42.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on NXTC. Zacks Research raised shares of NextCure from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 11th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of NextCure in a research report on Wednesday, July 15th. Weiss Ratings lowered shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 7th. Finally, Wall Street Zen downgraded shares of NextCure from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $19.00.

About NextCure

NextCure, Inc is a clinical?stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large?scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.